Inhibrx Biosciences: Plano na magsumite ng BLA para sa Ozekibart sa Q2 2026

Inihayag ng Inhibrx Biosciences ang mga plano na magsumite ng biologics license application (BLA) sa U.S. Food and Drug Administration para sa ozekibart sa ikalawang quarter ng 2026. Ito ay kasunod ng positibong topline results mula sa registrational trial ng ozekibart sa chondrosarcoma, kung saan natugunan nito ang primary endpoint.

Mahahalagang fact

Na-file: Nob 13, 2025, 11:00 PM
Kaganapan: Naisumite ang aplikasyon
Direksyon: Positibo
Kumpanya: INBXInhibrx
Asset: ozekibart
Pinagmulan: SEC 8-K
Kumpiyansa: May source

Sipi mula sa source

EX-99.1 2 exhibit99109302025.htm EX-99.1 Document Exhibit 99.1 Inhibrx Reports Third Quarter 2025 Financial Results San Diego, CA, November 14, 2025 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the “101 Transaction”) by Inhibrx, Inc. (the “Former Parent”) to Sanofi S.A. and the Former Parent’s concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials. Recent Corporate Highlights On October 23, 2025, Inhibrx announced positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and provided an update on its colorectal cancer and Ewing s

SEC 8-K